Novartis CAR-T therapy leads to durable response in lymphoma study – Reuters
Reuters |
Novartis CAR–T therapy leads to durable response in lymphoma study
Reuters Kymriah belongs to an exciting new class of therapy called CAR-T. It works by harvesting a patient’s own disease-fighting T–cells, genetically engineering them to target specific proteins on cancer cells, and replacing them to circulate possibly for … Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete …GlobeNewswire (press release) #ASH17: How does Novartis’ Kymriah DLBCL data stack up heading straight to a CAR–T showdown with Gilead?Endpoints News |
Financial Times |
Gilead dispels doubts with Car–T cancer drug trial results
Financial Times A pioneering cancer treatment being developed by the US biotech company Gilead Sciences can keep some of the sickest lymphoma patients alive for at least a year, according to the results of a much-anticipated clinical trial published on Sunday. The … ASH17: Benefit of Gilead’s CAR–T remains durable over longer termBioPharma Dive Gilead’s new drug keeps 56 percent of lymphoma trial patients aliveReuters Look back at pharma news to Dec 8The Pharma Letter Digital Journal all 7 news articles » |
Endpoints News |
‘Unheard of’ responses to bluebird CAR–T therapy seen in myeloma study
Reuters “This is unheard of, something that we haven’t seen with any drugs approved for myeloma in this type of population. The excitement among all the myeloma providers is crazy,” said Berdeja, director of myeloma research at the Sarah Cannon Center for … Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 …Business Wire (press release) BCMA-Directed bb2121 Highly Effective for MyelomaOncLive |
Seeking Alpha |
CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Therapy for β …
GlobeNewswire (press release) Data presented at ASH demonstrate that CRISPR Therapeutics’ proprietary CRISPR gene-editing approach results in high editing efficiency, with >90% of the hematopoietic stem cells edited at the target site. A vast majority of these cells are edited on … CRISPR Therapeutics: Analysis Of And Update On The B-Thalassemia FranchiseSeeking Alpha CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Therapy for ß …Nasdaq Crispr Therapeutics AG (NASDAQ:CRSP) Just Reported Increased ShortsWeeklyHub The Ledger Gazette –KL Daily –StockNewsTimes all 33 news articles » |